Provided by Tiger Trade Technology Pte. Ltd.

XORTX Therapeutics Inc.

1.88
-0.1650-8.09%
Volume:877
Turnover:1.70K
Market Cap:3.41M
PE:-0.68
High:1.88
Open:1.88
Low:1.88
Close:2.04
52wk High:7.05
52wk Low:1.73
Shares:1.82M
Float Shares:1.79M
Volume Ratio:0.34
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7455
EPS(LYR):-2.8052
ROE:-99.24%
ROA:-29.85%
PB:0.62
PE(LYR):-0.67

Loading ...

Company Profile

Company Name:
XORTX Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
3710 - 33rd Street NW,Calgary,Alberta,Canada
Zip Code:
T2L 2M1
Fax:
- -
Introduction:
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

Directors

Name
Position
Allen Davidoff
Chief Executive Officer and Director and President
Depesh Narotam
Independent Director
Paul Van Damme
Independent Director
Raymond Pratt
Independent Director
Krysta Davies Foss
Director

Shareholders

Name
Position
Allen Davidoff
Chief Executive Officer and Director and President
Mika Grasso
Co-Chief Executive Officer
Michael Bumby
Chief Financial Officer
Stacy Evans
Chief Business Officer
Stephen Haworth
Chief Medical Officer